One of three CD20 X CD3 bispecific antibody candidates striving for a 2023 thumbs up in late-stage diffuse large B-cell lymphoma (DLBCL), Genmab A/S and partner AbbVie Inc.’s epcoritamab is set to be filed in the EU later this year. The firms are also preparing for a US filing in large B-cell lymphoma.
While chimeric antigen receptor (CAR) T-cell drugs such as Kite Pharma’s Yescarta (axicabtagene ciloleucel) have recently won approval in DLBCL, the Biomedtracker analysts noted bispecific assets boast off-the-shelf convenience and remove the need for lymphodepletion